Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Myleoencephalitis; This serious case was reported by a consumer via interactive digital media and described the occurrence of encephalomyelitis in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, 1 week after receiving Shingles vaccine, the patient experienced encephalomyelitis (Verbatim: Myleoencephalitis) (serious criteria disability and GSK medically significant). The outcome of the encephalomyelitis was not reported. It was unknown if the reporter considered the encephalomyelitis to be related to Shingles vaccine. The company considered the encephalomyelitis to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 17-MAR-2025 This case was reported by a reporter via interactive digital media. The reporter reported that he/she knew two people (2 patients) now who have got the Shingles shot and one to two weeks later got myleoencephalitis and now they were disabled.; Sender's Comments: Encephalomyelitis is an unlisted event which is considered unrelated to GSK vaccine Shingles vaccine.